Right Heart Failure

Clinical Evidence

Image of a graph featuring Impella RP CVAD post-approval study outcomes

Overview

Impella RP is the most studied right-sided device and the only percutaneous technology with FDA approval designating it as safe and effective for right-heart support. Its exclusive FDA approval is a result of more than eight years of clinical studies.

RECOVER RIGHT: Safety & Efficacy

73% overall survival-to-discharge at 30 days¹

All patients discharged were alive at 180 days¹

Sustained hemodynamic improvement after Impella RP^® support¹

Increase in cardiac index (CI)
Decrease in central venous pressure (CVP)
Fewer benchmark adverse events at 30 days¹ compared to other RVAD studies
Death, bleeding, hemolysis
Neurologic dysfunction and limb ischemia

Resources from the Education Library

National Cardiogenic Shock Initiative (NCSI) Study Findings Regarding Right Ventricular Dysfunction

Babar Basir, DO, discusses findings on right heart dysfunction from the NCSI Study.

Multivessel Versus Culprit Vessel PCI in Cardiogenic Shock

Alejandro Lemor, MD, MS, discusses multivessel PCI versus culprit vessel PCI in patients with cardiogenic shock from the NCSI Study.

Updates from the Cardiogenic Shock Working Group

Navin Kapur, MD, and Mark Anderson, MD, discuss cardiogenic shock treatment strategies and algorithms for managing patients in cardiogenic shock.

The Procedure

View the step-by-step guide to right heart unloading with the Impella RP heart pump and explore best practices.

References

Anderson MB, et al. J Heart Lung Transplant. 2015; 34(12):1549-1560

NPS-1191